Clinical Trial Update: The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluated antibody persistence up to 15 years after a single booster dose of Encepur Adults (GSK) vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Virus Diseases

Drugs mentioned

• Encepur Adults

Snippet

Sponsor: GlaxoSmithKline | Conditions: Virus Diseases | Phase 4 | Status: COMPLETED | Results posted: 2024-03-28